The Global TB Caucus will host the second meeting of the Platform of Experts on 2 December 2021. The meeting will be centered on the need to implement the Multisectoral accountability framework, focusing particularly on the parliamentarians' checklist developed by the Global TB Caucus and piloted in the Eastern Europe and Central Asia region.

The Stop TB Partnership will host an official side-event, Undernutrition causes 20% of world’s TB cases. What to do?, at Tokyo Nutrition for Growth Summit 2021 on 6 December 2021.

India has the highest population with household exposure to pulmonary tuberculosis (TB), and therefore an increased risk of infection, a new study published in The Lancet November 21, 2021, flagged.

To mark the United Nations International Day of Persons with Disabilities, the World Health Organization (WHO) will host a special webinar, Preventing and addressing TB-related disabilities and improving quality of life, on 2 December 2021.

Every day, more than 650 children around the world die from tuberculosis – largely because they have never had the chance to be diagnosed and treated. 

Six years ago, Michael Niederweis, Ph.D., described the first known toxin of the deadly pathogen Mycobacterium tuberculosis (Mtb), an exotoxin that had gone undetected for 132 years. 

In the face of the COVID-19 pandemic, tuberculosis mortality has started to increase for the first time in a decade. In 2020 alone, more than 1.5 million people died from TB. Every year, about half a million people develop a drug-resistant form of TB (DR-TB).

24 November 2021 | Geneva -- The World Health Organization’s (WHO’s) 2021 Model Lists of Essential Medicines feature key updates to the TB section including the addition of moxifloxacin and rifapentine for the indication of drug susceptible TB, child friendly formulations of bedaquiline and delamanid to treat drug resistant TB and a higher dose formulation of rifapentine for TB preventive treatment. Further updates include the addition of other TB medicines to the list as well as the removal of some TB medicines that are no longer considered essential. The revised list provides a comprehensive list of quality assured TB medicines for TB preventive treatment as well as for the treatment of drug susceptible and drug resistant TB. 

Cellular study of telaprevir shows that the antiviral blocks the function of essential proteins in bacteria, revealing opportunity to repurpose drug to use alongside antibiotics.

The World Health Organization (WHO) Global TB Program is organizing an Information Session for civil society representatives to provide an update on WHO TB guidelines development on 10 December 2021.